Wenbin Jiang Cytek Biosciences, Inc. (CTKB) insider trading activity

Wenbin Jiang is PRESIDENT AND CEO of Cytek Biosciences, Inc.. Currently has a direct ownership of 5.19 Million shares of CTKB, which is worth approximately $32.8 Million. The most recent transaction as insider was on Nov 18, 2024, when has been sold 9,897 shares (Common Stock) at a price of $6.03 per share, resulting in proceeds of $59,678. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.19M

0.6% 3M change

1.9% 12M change

Total Value Held $32.8 Million

Wenbin Jiang Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 18 2024	SELL Payment of exercise price or tax liability	$59,678 $6.03 p/Share	9,897 Reduced 0.19%	5,187,638 Common Stock
Nov 18 2024	BUY Exercise of conversion of derivative security	-	40,639 Added 0.78%	5,193,020 Common Stock
Sep 14 2024	SELL Bona fide gift	-	200,000 Reduced 3.73%	5,156,896 Common Stock
Aug 19 2024	SELL Payment of exercise price or tax liability	$54,730 $5.53 p/Share	9,897 Reduced 0.18%	5,356,896 Common Stock
Aug 19 2024	BUY Exercise of conversion of derivative security	-	40,639 Added 0.75%	5,362,278 Common Stock
May 20 2024	SELL Payment of exercise price or tax liability	$42,327 $5.96 p/Share	7,102 Reduced 0.13%	5,326,154 Common Stock
May 20 2024	BUY Exercise of conversion of derivative security	-	29,345 Added 0.55%	5,329,742 Common Stock
Mar 11 2024	SELL Payment of exercise price or tax liability	$33,544 $7.22 p/Share	4,646 Reduced 0.09%	5,303,911 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	-	15,708 Added 0.3%	5,308,557 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$16,793 $8.38 p/Share	2,004 Reduced 0.04%	5,292,849 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	-	6,758 Added 0.13%	5,294,853 Common Stock
Nov 18 2023	SELL Payment of exercise price or tax liability	$37,315 $5.98 p/Share	6,240 Reduced 0.12%	5,288,095 Common Stock
Nov 18 2023	BUY Exercise of conversion of derivative security	-	18,539 Added 0.35%	5,292,060 Common Stock
Nov 07 2023	SELL Open market or private sale	$86,800 $4.34 p/Share	20,000 Reduced 0.38%	5,275,796 Common Stock
Oct 09 2023	SELL Open market or private sale	$106,600 $5.33 p/Share	20,000 Reduced 0.38%	5,295,796 Common Stock
Sep 14 2023	SELL Bona fide gift	-	2,290,000 Reduced 30.11%	5,315,796 Common Stock
Sep 07 2023	SELL Open market or private sale	$136,600 $6.83 p/Share	20,000 Reduced 0.26%	7,605,796 Common Stock
Aug 18 2023	SELL Payment of exercise price or tax liability	$52,536 $8.46 p/Share	6,210 Reduced 0.08%	7,625,796 Common Stock
Aug 18 2023	BUY Exercise of conversion of derivative security	-	18,539 Added 0.24%	7,629,761 Common Stock
Aug 07 2023	SELL Open market or private sale	$180,799 $9.04 p/Share	20,000 Reduced 0.26%	7,613,467 Common Stock
Jul 07 2023	SELL Open market or private sale	$169,600 $8.48 p/Share	20,000 Reduced 0.26%	7,633,467 Common Stock
Jun 07 2023	SELL Open market or private sale	$164,600 $8.23 p/Share	20,000 Reduced 0.26%	7,653,467 Common Stock
May 18 2023	SELL Payment of exercise price or tax liability	$37,356 $6.69 p/Share	5,584 Reduced 0.07%	7,673,467 Common Stock
May 18 2023	BUY Exercise of conversion of derivative security	-	14,612 Added 0.19%	7,676,418 Common Stock
May 08 2023	SELL Open market or private sale	$231,000 $11.55 p/Share	20,000 Reduced 0.26%	7,664,439 Common Stock

Wenbin Jiang

PRESIDENT AND CEO

Fremont, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTKB shares.

Notify only if

Value

Insider Trading

Get notified when an Cytek Biosciences, Inc. insider buys or sells CTKB shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cytek Biosciences, Inc.

Track Activities on CTKB

Account